Major Depressive Disorder (MDD) - Drug Pipeline Analysis and Market Forecasts to 2015

Major Depressive Disorder (MDD) - Drug Pipeline Analysis and Market Forecasts to 2015

Original Source: Drug Market

Buy Now: Market Research

Browse all : Pharmaceut Market Research

GlobalData, the industry analysis specialist, has released its new report, "Major Depressive Disorder - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Major depressive Disorder (MDD) therapeutics market. The report identifies the key trends shaping and driving the global MDD therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global MDD sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates the global MDD therapeutics market to be valued at $11.02bn in 2009. The market is estimated to decline by 3% to $9.0bn in 2017, which is attributed to patent expiry of Lexapro and Cymbalta in 2012 and 2013. However, the MDD market is anticipated to stabilize with the expected approval of Vilazodone and TC-5214 and the increasing public awareness.

Scope

The scope of the report includes:

Annualized global Hepatitis B therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.

Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.

Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include selective serotonin reuptake inhibitor, serotonin and nenorepinephrine reuptake inhibitor, cortiocotropin releasing factor antagonist and AMPA receptor modulator.

Analysis of the current and future market competition in the global MDD therapeutics market. The key future market players covered are GlaxoSmithkline, AstraZeneca, Forest Laboratories, Merck & Co., Eli Lilly, Weyth (Pfizer) and Lundbeck.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the MDD therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global MDD therapeutics market in the future.

GlobalData, the industry analysis specialist, has released its new report, "Major Depressive Disorder - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Major depressive Disorder (MDD) therapeutics market. The report identifies the key trends shaping and driving the global MDD therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global MDD sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates the global MDD therapeutics market to be valued at $11.02bn in 2009. The market is estimated to decline by 3% to $9.0bn in 2017, which is attributed to patent expiry of Lexapro and Cymbalta in 2012 and 2013. However, the MDD market is anticipated to stabilize with the expected approval of Vilazodone and TC-5214 and the increasing public awareness.

Scope

The scope of the report includes:

Annualized global Hepatitis B therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.

Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.

Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include selective serotonin reuptake inhibitor, serotonin and nenorepinephrine reuptake inhibitor, cortiocotropin releasing factor antagonist and AMPA receptor modulator.

Analysis of the current and future market competition in the global MDD therapeutics market. The key future market players covered are GlaxoSmithkline, AstraZeneca, Forest Laboratories, Merck & Co., Eli Lilly, Weyth (Pfizer) and Lundbeck.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the MDD therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global MDD therapeutics market in the future.

POST COMMENT

The Use of Surveillance Cameras for Store Market Planning Website Features and funtionality for Online Marketing Rule Your Web Market with PPC Management! E-Marketing Continues to be a Leader Combining Email Marketing with Other Types of Marketing Medical Polymers Market To 2015 - Polyvinyl Chloride (pvc) Dominating The Medical Devices Direct Mailing Lists Bulls-eye Marketing Neurelec Market Share Analysis Aarkstore Enterprise Pakistani Defense Sector - Market Opportunities And Entry Strategies, Analyses And Forecasts To 2015 Personalized Medicine Market - Advances In Human Genomics And Proteomics To Challenge Traditional The Polish Defense Sector - Market Opportunities And Entry Strategies, Analyses And Forecasts Creating Email Lists for Marketing Campaigns 10 Methods to Promote Your Text Marketing Mobile Call to Action